Literature DB >> 8969931

Effects of taxol on the human NCI-H295 adrenocortical carcinoma cell line.

F Fallo1, C Pilon, L Barzon, M Pistorello, U Pagotto, G Altavilla, M Boscaro, N Sonino.   

Abstract

We investigated the effects of taxol, an antimicrotubule agent active in different cancers, on the human NCI-H295 steroid-secreting adrenocortical carcinoma cell line. Cells were incubated for 48, 72 or 96 h with taxol 10(-10)-10(-4) M. Cell viability was evaluated by MTT assay with IC50 calculation. Apoptosis was investigated by measuring DNA fragmentation with ELISA assay after cell exposure to taxol at IC50 for 24 h. For secretion studies, aldosterone, cortisol, testosterone and dehydroepiandrosterone-sulphate (DHEA-S) were measured by RIA in the conditioned medium after 96 h exposure to taxol 10(-10)-10(-6) M, and expressed as percentage of steroid production by control cells. By MTT, taxol induced a dose-dependent inhibition of cell proliferation, with ICs50 at 72-96 h corresponding to blood levels achieved in vivo in patients with other types of cancer. Nuclear fragmentation, morphologically confirmed at electron microscopy, showed a 4-fold increase after exposure to taxol. With 10(-6) M taxol, aldosterone decreased to 48%, cortisol to 61%, testosterone to 76% and DHEA-S to 89% of steroid production by control cells. Taxol is an effective cytotoxic and antiproliferative agent in a human adrenocortical steroid-secreting carcinoma cell line. Apoptosis induced by the drug is involved in neoplastic cell death.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8969931     DOI: 10.1080/07435809609043766

Source DB:  PubMed          Journal:  Endocr Res        ISSN: 0743-5800            Impact factor:   1.720


  8 in total

Review 1.  Current perspective in the diagnosis and treatment of adrenocortical carcinoma.

Authors:  D E Schteingart
Journal:  Rev Endocr Metab Disord       Date:  2001-08       Impact factor: 6.514

2.  Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function.

Authors:  Joseph F Cotten; Stuart A Forman; Joydev K Laha; Gregory D Cuny; S Shaukat Husain; Keith W Miller; Hieu H Nguyen; Elizabeth W Kelly; Deirdre Stewart; Aiping Liu; Douglas E Raines
Journal:  Anesthesiology       Date:  2010-03       Impact factor: 7.892

Review 3.  Human adrenocortical carcinoma cell lines.

Authors:  Tao Wang; William E Rainey
Journal:  Mol Cell Endocrinol       Date:  2011-09-05       Impact factor: 4.102

Review 4.  Cytotoxic treatment of adrenocortical carcinoma.

Authors:  H Ahlman; A Khorram-Manesh; S Jansson; B Wängberg; O Nilsson; C E Jacobsson; S Lindstedt
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

5.  Development of a toxicogenomics signature for genotoxicity using a dose-optimization and informatics strategy in human cells.

Authors:  Heng-Hong Li; Daniel R Hyduke; Renxiang Chen; Pamela Heard; Carole L Yauk; Jiri Aubrecht; Albert J Fornace
Journal:  Environ Mol Mutagen       Date:  2015-03-02       Impact factor: 3.216

6.  Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study.

Authors:  T Urup; W Z Pawlak; P M Petersen; H Pappot; M Rørth; G Daugaard
Journal:  Br J Cancer       Date:  2013-05-07       Impact factor: 7.640

7.  The effects of mitotane and 1α,25-dihydroxyvitamin D3 on Wnt/beta-catenin signaling in human adrenocortical carcinoma cells.

Authors:  B Rubin; C Pilon; R Pezzani; A Rebellato; F Fallo
Journal:  J Endocrinol Invest       Date:  2019-10-05       Impact factor: 4.256

Review 8.  Adrenal cortical carcinoma.

Authors:  R P Boushey; A P Dackiw
Journal:  Curr Treat Options Oncol       Date:  2001-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.